



Balfour Capital Group Bristol-Myers Squibb Company

Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Its product portfolio spans oncology, immunology, cardiovascular diseases, hematology, and neuroscience. Notable products include Opdivo, Yervoy, Eliquis, and the recently launched schizophrenia drug Cobenfy.

1. Top 5 Competitors

BMS competes with several major pharmaceutical companies:

1. Merck & Co.
2. Johnson & Johnson
3. Pfizer
4. AstraZeneca
5. Daiichi Sankyo

2. Largest Institutional Shareholders

Institutional investors hold approximately 76.41% of BMS shares. The top institutional shareholders are:

- BlackRock Inc. – \$11.04 billion
- Vanguard Group Inc. – \$10.74 billion
- State Street Corp. – \$4.81 billion
- Charles Schwab Investment Management Inc.

3. Management Team

Key members of BMS's leadership include:

- Christopher S. Boerner – Chief Executive Officer and Chairman
- Samit Hirawat, MD – Executive Vice President, Chief Medical Officer and Head of Development
- Cari Gallman – Executive Vice President, General Counsel and Chief Policy Officer
- Ben Hickey – President, RayzeBio



Balfour Capital Group Bristol-Myers Squibb Company

4. Revenue

In Q1 2025, BMS reported revenues of \$11.2 billion, a 6% decrease year-over-year. Despite this, the company raised its full-year revenue guidance to a range of \$45.8 billion to \$46.8 billion.

5. Institutions with Buy Recommendations:

Several institutions have issued buy recommendations for BMS:

- Nasdaq: Analysts suggest BMS is an attractive investment at its current valuation.
- TipRanks: Out of 43 analysts, 9 have issued Buy ratings.

6. Analyst Sentiment Summary

Analyst consensus for BMS is generally positive:

- TipRanks: 9 Buy, 30 Hold, 4 Sell ratings; average price target of \$56.06.
- MarketWatch: Average recommendation is Hold; average target price of \$56.05.
- Marketscreener: Mean consensus is Hold; average target price of \$57.20.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, insider activity includes:

- Purchases:
 - EVP Samit Hirawat bought shares worth approximately \$202,215 on April 25, 2025.
 - CEO Christopher Boerner purchased shares worth \$110,096 on February 20, 2025.
- Sales:
 - In the past 12 months, insiders sold approximately 215,373 shares.